Senior Director
Revolution Medicines
Senior Director
Revolution Medicines
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.
Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.
The Opportunity:
The Senior Director, HEOR/RWE is responsible for developing the strategy and executing HEOR plans and activities related to all Revolution Medicines assets intended for use in non-small cell lung cancer (NSCLC). They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally. The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology.
Reporting to the Executive Director of HEOR/RWE Lung, the Senior Director, HEOR/RWE :
Align with Medical Affairs and Development leadership to design research and deliver evidence consistent with the medical strategy and IEP.
Develops and evolves product HEOR/RWE strategy globally, including integration with development, commercial, regulatory, and market access planning.
Deliver HEOR/RWE tactics with quality and in alignment with agreed upon timing.
Provide HEOR/RWE leadership on matrix teams and working groups.
Work with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams.
Provide HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies.
Leads enterprise partnerships with payers, HTA agencies, and global consortia to help shape access strategy, policies, evidence standards, and evidence generation activities.
Effectively present research findings to internal and external stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders.
Facilitate the communication of the value proposition of Revolution Medicines’ portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions.
Engage and collaborate with external partners including payers, health care providers, thought leaders, patient advocates, and decision-makers to establish/maintain strong partnerships and gather insights into research programs.
Facilitate and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care.
Stay up to date with and add to the advancements in health economics methodologies and best practices.
Identify and interface with HEOR & RWE experts and organizations, profile data sources and related organizations as they relate to Revolution Medicines’ portfolio and therapeutic areas.
Closely monitor new trends in health policy and payer environment, assess competitive data gaps and communicate to the organization, to help Revolution Medicines build industry-leading capabilities and be on the cutting edge of evidence-based medicine and HEOR research.
Required Skills, Experience and Education:
Deep expertise in health economics, outcomes research, patient-reported outcomes or related fields in the biotechnology or pharmaceutical industry.
Experience in oncology HEOR and RWE development.
Track record of high impact publications in HEOR/RWE topics.
Strong written and interpersonal communication skills, with an ability to present complex technical information clearly.
Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models.
Ability to establish relationships with experts in real world evidence (RWE) and therapeutic areas of interest.
Preferred Skills:
12+ years of relevant experience in the pharmaceutical/biotech industry.
Global launch experience.
Experience related to NSCLC.
#LI-VN1 #LI-Hybrid
The base pay salary range for this full-time position for candidates working onsite at our headquarters in Redwood City, CA is listed below. The range displayed on each job posting is intended to be the base pay salary range for an individual working onsite in Redwood City and will be adjusted for the local market a candidate is based in. Our base pay salary ranges are determined by role, level, and location. Individual base pay salary is determined by multiple factors, including job-related skills, experience, market dynamics, and relevant education or training.
Please note that base pay salary range is one part of the overall total rewards program at RevMed, which includes competitive cash compensation, robust equity awards, strong benefits, and significant learning and development opportunities.
Revolution Medicines is an equal opportunity employer and prohibits unlawful discrimination based on race, color, religion, gender, sexual orientation, gender identity/expression, national origin/ancestry, age, disability, marital status, medical condition, and veteran status.
Revolution Medicines takes protection and security of personal data very seriously and respects your right to privacy while using our website and when contacting us by email or phone. We will only collect, process and use any personal data that you provide to us in accordance with our CCPA Notice and Privacy Policy. For additional information, please contact [email protected].
We are aware of recent recruitment scams in which individuals or organizations falsely represent themselves as being affiliated with Revolution Medicines. These scams may appear as false job advertisements or unsolicited contacts through communication or chat platforms, email, phone, or text message.
Please note that Revolution Medicines does not extend unsolicited employment offers and will never ask candidates to provide financial information, purchase equipment, or pay fees as part of the hiring process. All legitimate communication from Revolution Medicines will come from an official @revmed.com email address.
If you believe you’ve been contacted by someone impersonating a Revolution Medicines recruiter, please report it to [email protected] so we can share these impersonations with our IT team for tracking and awareness.
Base Pay Salary Range 244000 - 305000 USD
Clinical-stage oncology company developing RAS inhibitors
Revolution Medicines develops precision oncology drugs focused on cancers driven by RAS mutations. Its RAS(ON) inhibitors are small molecules that bind the active form of RAS to block cancer signaling, with candidates like Daraxonrasib (RMC-6236), Elironrasib (RMC-6291), and Zoldonrasib (RMC-9805) advancing in global Phase 3 trials. The company funds its research through collaborations, royalties, and upfront funding, and has not yet marketed a product. Its goal is to bring effective RAS-targeted therapies to patients and advance multiple candidates through late-stage trials toward approval, supported by strong cash reserves.
Explore more opportunities at Revolution Medicines